• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Gregory C. Garland Named to ExxonMobil Board of Directors

    10/29/25 5:00:00 PM ET
    $AMGN
    $XOM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Integrated oil Companies
    Energy
    Get the next $AMGN alert in real time by email

    Exxon Mobil Corporation (NYSE:XOM) announced today that Gregory C. Garland has been elected to its board of directors, effective November 3, 2025.

    "Greg brings to the ExxonMobil board more than a decade of experience as the CEO of respected industry companies," said ExxonMobil Chairman and CEO Darren Woods. "All of us on the board and senior management will benefit from his deep expertise in our industry and his well-earned reputation for collaboration and candor."

    "We're pleased to welcome Greg to the Board as the company stays focused on developing advantaged assets and delivering new projects that add value, while lowering costs and prioritizing shareholder returns for the long-term," said Joseph Hooley, lead independent director for Exxon Mobil Corporation. "With his global business perspective and proven leadership in the energy industry, he brings valuable strengths that will enhance our current capabilities."

    Mr. Garland was Chair and CEO of Phillips 66 from 2012 to 2022, Executive Chair from 2022 to 2024, and before that was President and CEO of Chevron Phillips Chemical Company from 2008 to 2010.

    He has served on the Board of Directors of Amgen Inc. (NASDAQ:AMGN), a leading biotechnology company, since 2013. His other affiliations include the Barbara Bush Literacy Foundation (Board Vice Chair), Memorial Hermann Foundation (Director), and the M.D. Anderson Cancer Center (President's Advisory Council member).

    About ExxonMobil

    ExxonMobil, one of the largest publicly traded international energy and petrochemical companies, creates solutions that improve quality of life and meet society's evolving needs.

    The corporation's primary businesses - Upstream, Product Solutions and Low Carbon Solutions – provide products that enable modern life, including energy, chemicals, lubricants, and lower emissions technologies. ExxonMobil holds an industry-leading portfolio of resources, and is one of the largest integrated fuels, lubricants, and chemical companies in the world. ExxonMobil also owns and operates the largest CO2 pipeline network in the United States. In 2021, ExxonMobil announced Scope 1 and 2 greenhouse gas emission-reduction plans for 2030 for operated assets, compared to 2016 levels. The plans are to achieve a 20-30% reduction in corporate-wide greenhouse gas intensity; a 40-50% reduction in greenhouse gas intensity of upstream operations; a 70-80% reduction in corporate-wide methane intensity; and a 60-70% reduction in corporate-wide flaring intensity. To learn more, visit exxonmobil.com and ExxonMobil's Advancing Climate Solutions.

    Cautionary Statement

    Statements about conditions or future events in this release are forward-looking statements. Actual results in the future, including business plans, schedules, capacities, production rates, and resource extraction could differ materially due to: changes in market conditions that affect supply and demand in the oil and gas industry; political or regulatory developments around the world that may include obtaining necessary regulatory permits; reservoir performance; the outcome of future exploration efforts; timely completion of development and construction projects; technical or operating factors; and other factors cited under the caption "Factors Affecting Future Results" on the Investors page of our website at exxonmobil.com and under Item 1A. Risk Factors in our annual report on Form 10-K. References to "recoverable resources," "oil-equivalent barrels," and other quantifies of oil and gas include estimated quantities that are not yet classified as proved reserves under SEC definitions but are expected to be ultimately recoverable. The term "project" can refer to a variety of different activities and does not necessarily have the same meaning as in any government payment transparency reports.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251029667241/en/

    Media Relations

    (737) 272-1452

    Get the next $AMGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMGN
    $XOM

    CompanyDatePrice TargetRatingAnalyst
    Exxon Mobil Corporation
    $XOM
    10/17/2025$156.00Overweight
    Wells Fargo
    Amgen Inc.
    $AMGN
    9/3/2025Mkt Perform
    Raymond James
    Exxon Mobil Corporation
    $XOM
    8/20/2025$111.00Hold
    Melius
    Exxon Mobil Corporation
    $XOM
    6/23/2025$120.00 → $128.00Buy
    TD Cowen
    Amgen Inc.
    $AMGN
    5/20/2025$288.00Neutral
    Guggenheim
    Amgen Inc.
    $AMGN
    4/22/2025$305.00Neutral
    Cantor Fitzgerald
    Exxon Mobil Corporation
    $XOM
    12/16/2024$132.00 → $128.00Buy
    TD Cowen
    Amgen Inc.
    $AMGN
    12/10/2024$256.00Underperform
    BofA Securities
    More analyst ratings

    $AMGN
    $XOM
    SEC Filings

    View All

    Amgen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AMGEN INC (0000318154) (Filer)

    11/4/25 4:04:18 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exxon Mobil Corporation filed SEC Form 8-K: Leadership Update

    8-K - EXXON MOBIL CORP (0000034088) (Filer)

    11/3/25 3:14:35 PM ET
    $XOM
    Integrated oil Companies
    Energy

    SEC Form 10-Q filed by Exxon Mobil Corporation

    10-Q - EXXON MOBIL CORP (0000034088) (Filer)

    11/3/25 12:45:47 PM ET
    $XOM
    Integrated oil Companies
    Energy

    $AMGN
    $XOM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Garland Greg C. was granted 8,000 shares, increasing direct ownership by 2,360% to 8,339 units (SEC Form 4)

    4 - EXXON MOBIL CORP (0000034088) (Issuer)

    11/4/25 12:11:22 PM ET
    $XOM
    Integrated oil Companies
    Energy

    New insider Garland Greg C. claimed ownership of 339 shares (SEC Form 3)

    3 - EXXON MOBIL CORP (0000034088) (Issuer)

    11/3/25 4:49:48 PM ET
    $XOM
    Integrated oil Companies
    Energy

    VP - Corp Strategic Planning Talley Darrin L sold $238,351 worth of shares (2,158 units at $110.45) (SEC Form 4)

    4 - EXXON MOBIL CORP (0000034088) (Issuer)

    8/25/25 12:40:29 PM ET
    $XOM
    Integrated oil Companies
    Energy

    $AMGN
    $XOM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Exxon Mobil with a new price target

    Wells Fargo initiated coverage of Exxon Mobil with a rating of Overweight and set a new price target of $156.00

    10/17/25 8:34:26 AM ET
    $XOM
    Integrated oil Companies
    Energy

    Raymond James resumed coverage on Amgen

    Raymond James resumed coverage of Amgen with a rating of Mkt Perform

    9/3/25 8:26:50 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Melius initiated coverage on Exxon Mobil with a new price target

    Melius initiated coverage of Exxon Mobil with a rating of Hold and set a new price target of $111.00

    8/20/25 8:52:47 AM ET
    $XOM
    Integrated oil Companies
    Energy

    $AMGN
    $XOM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    11/21/24 12:43:07 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for PAVBLU issued to AMGEN INC

    Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:

    8/26/24 5:53:38 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    8/21/24 12:12:47 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $XOM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

    THOUSAND OAKS, Calif., Nov. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2025.  "We delivered strong volume growth this quarter, reflecting the demand for our medicines and the impact we're having on patients worldwide. With disciplined investment and a pipeline of first-in-class medicines, we're focused on expanding access, advancing innovation, and sustaining long-term growth," said Robert A. Bradway, chairman and chief executive officer. Key results include: For the third quarter, total revenues increased 12% to $9.6 billion in comparison to the third quarter of 2024.Product sales grew 12%, driven by 14% volume growth, partially o

    11/4/25 4:01:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND

    THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the fourth quarter of 2025. The dividend will be paid on December 12, 2025, to all stockholders of record as of the close of business on November 21, 2025. About AmgenAmgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is adv

    10/31/25 4:01:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025

    Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE Trial Reinforces Its Position as a Leading LDL-C Lowering Therapy for Reducing Cardiovascular Events THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its cardiovascular portfolio, including late-breaking results from the Phase 3 VESALIUS-CV clinical trial of Repatha® (evolocumab), will be presented at the American Heart Association Scientific Sessions taking place November 7-10, 2025, in New Orleans, LA. Results from the landmark Phase 3 VES

    10/31/25 9:00:00 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $XOM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dreyfus Maria S. bought $2,000,386 worth of shares (18,310 units at $109.25), increasing direct ownership by 105% to 35,757 units (SEC Form 4)

    4 - EXXON MOBIL CORP (0000034088) (Issuer)

    6/20/24 9:38:43 AM ET
    $XOM
    Integrated oil Companies
    Energy

    Ubben Jeffrey W bought $26,491,420 worth of shares (250,000 units at $105.97) (SEC Form 4)

    4 - EXXON MOBIL CORP (0000034088) (Issuer)

    11/8/23 4:30:11 PM ET
    $XOM
    Integrated oil Companies
    Energy

    SEC Form 4: Amgen Inc converted options into 33,603,948 shares and bought $29,999,985 worth of shares (1,764,705 units at $17.00)

    4 - AMGEN INC (0000318154) (Reporting)

    9/19/23 7:52:07 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $XOM
    Leadership Updates

    Live Leadership Updates

    View All

    NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer

    NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer Ingelheim senior leader joins NodThera Leadership TeamWill spearhead clinical advancement of the company's innovative NLRP3 inflammasome inhibitor portfolioBrings deep clinical leadership in obesity and cardiometabolic diseases, with a proven track record guiding programs from early-stage development through Phase 3 and regulatory approval Philadelphia, PA, July 21, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appoi

    7/21/25 7:00:00 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GeminiBio Appoints Mike Stella to Board

    Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

    2/18/25 9:00:00 AM ET
    $AMGN
    $GSK
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    RPM Announces Appointment of Three New Board Members

    RPM International Inc. (NYSE:RPM) today announced the appointment of three individuals, Craig S. Morford, Christopher L. Mapes and Julie A. Beck, to its board of directors. These appointments reflect RPM's ongoing commitment to expanding the expertise, diversity and leadership capabilities of its board as the company continues to drive long-term growth and shareholder value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113146614/en/Christopher L. Mapes (Photo: Business Wire) The appointments of Mr. Morford and Mr. Mapes are effective immediately, and Ms. Beck's term is set to commence on April 7, 2025. With these additions,

    1/13/25 4:45:00 PM ET
    $AOS
    $CAH
    $LECO
    Consumer Electronics/Appliances
    Consumer Discretionary
    Other Pharmaceuticals
    Health Care

    $AMGN
    $XOM
    Financials

    Live finance-specific insights

    View All

    AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

    THOUSAND OAKS, Calif., Nov. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2025.  "We delivered strong volume growth this quarter, reflecting the demand for our medicines and the impact we're having on patients worldwide. With disciplined investment and a pipeline of first-in-class medicines, we're focused on expanding access, advancing innovation, and sustaining long-term growth," said Robert A. Bradway, chairman and chief executive officer. Key results include: For the third quarter, total revenues increased 12% to $9.6 billion in comparison to the third quarter of 2024.Product sales grew 12%, driven by 14% volume growth, partially o

    11/4/25 4:01:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND

    THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the fourth quarter of 2025. The dividend will be paid on December 12, 2025, to all stockholders of record as of the close of business on November 21, 2025. About AmgenAmgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is adv

    10/31/25 4:01:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025

    Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE Trial Reinforces Its Position as a Leading LDL-C Lowering Therapy for Reducing Cardiovascular Events THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its cardiovascular portfolio, including late-breaking results from the Phase 3 VESALIUS-CV clinical trial of Repatha® (evolocumab), will be presented at the American Heart Association Scientific Sessions taking place November 7-10, 2025, in New Orleans, LA. Results from the landmark Phase 3 VES

    10/31/25 9:00:00 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $XOM
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Exxon Mobil Corporation on Jun 20

    Director Dreyfus Maria S. bought $2,000,386 worth of shares (18,310 units at $109.25), increasing direct ownership by 105% to 35,757 units (SEC Form 4) on June 20, 2024. This substantial insider purchase is a significant development for Exxon Mobil Corporation. As we delve into the recent insider activity at Exxon Mobil, we notice a few interesting patterns. Prior to Dreyfus Maria S.'s purchase, we observed that on January 4, 2024, Ubben Jeffrey W. granted 2,500 shares, which could signal confidence in the company. On the same day, Powell Dina H. claimed no ownership of stock but was granted 8,000 shares, indicating a new ownership stake. These events suggest a mix of adjustments in holding

    6/20/24 1:39:11 PM ET
    $XOM
    Integrated oil Companies
    Energy

    $AMGN
    $XOM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

    SC 13G/A - AMGEN INC (0000318154) (Subject)

    2/13/24 4:58:51 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Exxon Mobil Corporation (Amendment)

    SC 13G/A - EXXON MOBIL CORP (0000034088) (Subject)

    2/13/24 4:55:49 PM ET
    $XOM
    Integrated oil Companies
    Energy

    SEC Form SC 13G filed by Exxon Mobil Corporation

    SC 13G - EXXON MOBIL CORP (0000034088) (Subject)

    2/9/24 10:03:35 AM ET
    $XOM
    Integrated oil Companies
    Energy